Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® Soft Mist™ Inhaler in COPD

Abstract

Bronchoconstriction has been reported in asthma and chronic obstructive pulmonary disease (COPD) patients after administration of some aqueous inhalation solutions. We investigated the incidence of this event during long-term clinical trials of tiotropium delivered via Respimat® Soft Mist™ Inhaler (SMI). We retrospectively analyzed pooled data from two identical Phase III clinical trials, in which 1990 patients with COPD received 48 weeks’ treatment with once-daily tiotropium (5 or 10 μg) or placebo inhaled via Respimat® SMI. We recorded the incidence of bronchospasm and of a range of respiratory events that could suggest bronchoconstriction during the first 30 minutes after inhalation of study treatment on each of the eight test days. No patients reported bronchospasm. Six patients (0.3%) reported a combination of at least two events suggestive of bronchoconstriction, and 21 (1.1%) reported either rescue medication use or a respiratory adverse event. Asymptomatic falls in forced expiratory volume in one second (FEV1) of ≥15% were recorded on all test days, with no change in incidence over time, and affected 8.2% of those in the tiotropium groups and 14.5% of those on placebo. In COPD patients receiving long-term treatment with tiotropium 5 or 10 μg via Respimat® SMI, no bronchospasm was recorded, and the number of events possibly indicative of paradoxical bronchoconstriction was very low.

Radiological correlates and clinical implications of the paradoxical lung function response to β2 agonists: an observational study

“…1 However, improvements in lung function after short acting beta2-agonist and anticholinergic bronchodilators can be demonstrated in a significant proportion of patients with COPD. 2 There are also reports of a paradoxical response to beta2-agonists, resulting in bronchoconstriction and significant respiratory distress 3-5 and it is likely that asymptomatic bronchoconstriction occurs more frequently 6,7 though there has been no systematic study of this phenomenon. There are several potential reasons for a paradoxical response including an adverse reaction to either the bronchodilator itself or to inhaled preservatives or propellants.…”

Transient paradoxical bronchospasm associated with inhalation of the LAMA AZD9164: analysis of two Phase I, randomised, double-blind, placebo-controlled studies

“…It may be caused by an adverse reaction to the drug being administered or to the excipients, preservatives, surfactants, stabilisers or propellants used in its delivery [ 15 - 18 ]. Abrupt changes in osmolarity, temperature or pH in lung tissue resulting from inhalation of a drug aerosol, airflow turbulence, deep inhalation or expiration and repeated spirometry efforts may also trigger bronchospasm [ 16 , 19 , 20 ]. Which of these factors was involved in these studies is unclear, but the dual response to AZD9164 raises interesting scientific issues which will continue to be explored.…”

New abilities of administration of tiotropium bromide using the aerosol delivery device Respimat®

“…R.Hodder et al провели специальный анализ 1 го дичных исследований ТР (n = 1 990), посвященный выявлению парадоксальной бронхоконстрикции при использовании этого препарата [51], в результа те которого не обнаружено ни одного указания на развитие парадоксального бронхоспазма; 21 (1,1 %) больным отмечена необходимость использования быстродействующих бронхолитиков или развитие дыхательного дискомфорта; 6 (0,3 %) пациентами отмечен дискомфорт, потребовавший приема быст родействующего бронхолитика. При этом данные НЯ наблюдались и в группе плацебо.…”